Technologies

B-ME developed the first thermoplastic composite electrode film based on bio-derived and biodegradable polyesters and carbon nano-fibers. It is metal-free, highly electrically conductive and possess good thermo-mechanical properties, a challenging combination of three features in a single product. This is the first-of-its-kind product, as, to the best of our knowledge, no thermoplastic biobased electrode film has been effectively produced and used so far.

Inert biomedical devices with modular load-bearing function designed with peculiar multi-domain composite microstructures. The reference compositional system is Zirconia-Alumina with a prevailing overall composition of customizable zirconia or alumina. Examples of devices are 3D structures consisting of parts with differentiated functional properties, due to different composition/microstructure/architecture, and further functionalizable ex-post to favor and improve the stabilization of the implantation by newly formed bone in superior quantity and quality.

22q11.2DS(DGS) deletion syndrome is a rare and phenotypically variable multiorgan syndrome, currently without any cure. Our aim is to develop a standardized approach to formulate pharmacological products useful for clinical trials direct to prevent some serious clinical manifestations of adolescence and adulthood, such as neuropsychiatric and musculoskeletal diseases, or to eliminate or improve cardiovascular defects during embryonic development.

The procedure enables the fabrication of nanocomposite membranes filled with suitable amounts of exfoliated bidimensional crystals. These are obtained with an advanced wet-jet milling technique, which provides desired thickness and lateral size of nanofillers through the pulverization and colloidal homogenization of bulk nanomaterials. The bidimensional crystals are dispersed in fluids and suitably delivered inside polymeric matrixes exhibiting a singular morphology.

We have identified the presence of the poorly characterized precursor proNGF-A in human tissues, deposited its coding nucleotide sequence (GenBank MH358394) and demonstrated its neuroprotective and neurotrophic activity in vitro and in vivo. We inserted mutations into the native molecule, identified through computational analysis, which allow proNGF-A production by eukaryotic expression systems, through a method currently validated on a laboratory scale.

We have identified compounds that show a neuroprotective action in vivo, in models of neurodegenerative diseases (e.g. SMA, Parkinson, Alzheimer, Huntington) in the model organism C. elegans. These compounds consist of: mixtures of 22 natural extracts, 15 natural molecules and 11 synthetic molecules.